[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2018000597A1 - Métodos para tratar enfermedades inflamatorias - Google Patents

Métodos para tratar enfermedades inflamatorias

Info

Publication number
CL2018000597A1
CL2018000597A1 CL2018000597A CL2018000597A CL2018000597A1 CL 2018000597 A1 CL2018000597 A1 CL 2018000597A1 CL 2018000597 A CL2018000597 A CL 2018000597A CL 2018000597 A CL2018000597 A CL 2018000597A CL 2018000597 A1 CL2018000597 A1 CL 2018000597A1
Authority
CL
Chile
Prior art keywords
methods
inflammatory diseases
treat inflammatory
diseases
treat
Prior art date
Application number
CL2018000597A
Other languages
English (en)
Inventor
Paul Scholl
Wulf Otto Boecher
Annette Bettina Galler
Bojan LALOVIC
Steven John Padula
Sudha Visvanathan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2018000597A1 publication Critical patent/CL2018000597A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Esta invención se refiere generalmente a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular, enfermedades inflamatorias, tales como la enfermedad de Crohn, que utilizan anticuerpos anti-IL-23A.</p>
CL2018000597A 2015-09-18 2018-03-07 Métodos para tratar enfermedades inflamatorias CL2018000597A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562220410P 2015-09-18 2015-09-18
US201562235654P 2015-10-01 2015-10-01
US201662295643P 2016-02-16 2016-02-16
US201662328863P 2016-04-28 2016-04-28
US201662335242P 2016-05-12 2016-05-12
US201662339192P 2016-05-20 2016-05-20

Publications (1)

Publication Number Publication Date
CL2018000597A1 true CL2018000597A1 (es) 2018-07-27

Family

ID=57003593

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000597A CL2018000597A1 (es) 2015-09-18 2018-03-07 Métodos para tratar enfermedades inflamatorias

Country Status (16)

Country Link
US (1) US20170081402A1 (es)
EP (1) EP3350221A1 (es)
JP (6) JP6668461B2 (es)
KR (1) KR20180053395A (es)
CN (1) CN108026168A (es)
AU (2) AU2016323152A1 (es)
BR (1) BR112018003526A2 (es)
CA (1) CA2996645A1 (es)
CL (1) CL2018000597A1 (es)
EA (1) EA201890747A1 (es)
HK (1) HK1252037A1 (es)
IL (2) IL302197A (es)
MX (3) MX2018003174A (es)
PH (1) PH12018500578A1 (es)
TW (2) TWI733695B (es)
WO (1) WO2017048901A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030916T2 (en) 2010-11-04 2017-06-28 Boehringer Ingelheim Int Anti-IL-23 antibodies
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3677597A1 (en) * 2016-10-14 2020-07-08 Boehringer Ingelheim International GmbH Methods of treating diseases
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
TWI850365B (zh) 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN112578123B (zh) * 2019-09-27 2022-10-25 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
WO2022150472A1 (en) 2021-01-06 2022-07-14 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP2452694B1 (en) 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DK1937721T3 (da) * 2005-08-25 2010-10-18 Lilly Co Eli Anti-IL-23 antistoffer
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗ｉｌ−２３抗体、組成物、方法および用途
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
US20100111966A1 (en) * 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
HUE030916T2 (en) * 2010-11-04 2017-06-28 Boehringer Ingelheim Int Anti-IL-23 antibodies
KR102124758B1 (ko) * 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
CA2906384A1 (en) * 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
JP7060806B2 (ja) * 2018-08-22 2022-04-27 富士通株式会社 情報処理装置、データ管理方法およびデータ管理プログラム
JP2020030579A (ja) * 2018-08-22 2020-02-27 信越ポリマー株式会社 Ｒｆｉｄタグ埋設体およびその製造方法

Also Published As

Publication number Publication date
JP2020100643A (ja) 2020-07-02
KR20180053395A (ko) 2018-05-21
CN108026168A (zh) 2018-05-11
EP3350221A1 (en) 2018-07-25
AU2016323152A1 (en) 2018-02-22
JP6668461B2 (ja) 2020-03-18
HK1252037A1 (zh) 2019-05-10
IL302197A (en) 2023-06-01
AU2023203530A1 (en) 2023-07-06
TW202138008A (zh) 2021-10-16
US20170081402A1 (en) 2017-03-23
JP2022088478A (ja) 2022-06-14
JP2018527380A (ja) 2018-09-20
JP2024096863A (ja) 2024-07-17
MX2022015248A (es) 2023-01-11
MX2018003174A (es) 2018-05-17
TW201722474A (zh) 2017-07-01
TWI733695B (zh) 2021-07-21
MX2022015250A (es) 2023-01-11
JP7000476B2 (ja) 2022-02-04
CA2996645A1 (en) 2017-03-23
JP2020100644A (ja) 2020-07-02
IL257561A (en) 2018-04-30
PH12018500578A1 (en) 2018-09-10
WO2017048901A1 (en) 2017-03-23
TWI811716B (zh) 2023-08-11
JP2022046624A (ja) 2022-03-23
JP7477492B2 (ja) 2024-05-01
BR112018003526A2 (pt) 2018-09-25
EA201890747A1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR112017025003A2 (pt) composições compreendendo cepas bacterianas
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
BR112018009706A2 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
CL2016001871A1 (es) Anticuerpos humanos para pd-1
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
EA201790273A1 (ru) Флагеллиновые композиции и их применение
GT201700188A (es) Anticuerpos contra tau y sus usos
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
HK1248140A1 (zh) 用於治療癌症或免疫性疾病的細胞外基質組合物
ZA201901168B (en) Novel compounds for treating parasitic disease
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
MY195000A (en) Method for the treatment of neurological disease
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017025264A2 (pt) tratamento de prurido
CL2017002304A1 (es) Métodos para tratar enfermedades
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis